Zai Lab hauls in $761M from Hong Kong IPO to push Ze­ju­la, more bud­ding can­di­dates in Chi­na — re­port

Zai Lab is set to net more than $761 mil­lion from its sec­ondary list­ing in Hong Kong af­ter pric­ing the IPO at $72.51 (HKD$562) — just a hair be­low its Nas­daq clos­ing price on Mon­day, Bloomberg and Nikkei Asian Re­view re­port­ed.

A pi­o­neer in bring­ing West­ern drugs to Chi­na, co-founder and CEO Saman­tha Du has more than tripled Zai Lab’s mar­ket cap in the three years it’s been pub­lic in the US. The HKEX list­ing is de­signed to fund R&D and com­mer­cial­iza­tion for the cur­rent port­fo­lio while fu­el­ing new in-li­cens­ing pacts, the biotech wrote in a fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.